Overall market sentiment has been down on COMPASS Pathways PLC (CMPS) stock lately. CMPS receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With CMPS Stock Today?
COMPASS Pathways PLC (CMPS) stock is trading at $36.50 as of 10:17 AM on Thursday, Apr 15, an increase of $0.55, or 1.53% from the previous closing price of $35.95. The stock has traded between $36.50 and $37.94 so far today. Volume today is below average. So far 76,449 shares have traded compared to average volume of 370,750 shares.
To screen for more stocks like COMPASS Pathways PLC click here.
More About COMPASS Pathways PLC
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Click Here to get the full Stock Score Report on COMPASS Pathways PLC (CMPS) Stock.
